CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus

CHEPLAPHARM has held the rights for Atacand® and Atacand® Plus in 28 European markets since 2018. In autumn last year CHEPLAPHARM agreed with AstraZeneca to also acquire the global rights (excluding the US) for these two products and the deal was closed  successfully during the last week of December 2020.  

Atacand® (Candesartan Cilexetil) is a prescription medication used to treat heart failure and high blood pressure. The product was developed in collaboration between AstraZeneca and Takeda and first launched in 1997. AstraZeneca and CHEPLAPHARM agreed that AstraZeneca will continue to manufacture and supply Atacand® and Atacand® Plus and will continue to commercialise the medicines in the relevant territories during a three-year transition period. The transfer of the marketing authorizations and integration of the product into the manufacturing and distribution network of CHEPLAPHARM is therefore expected to be finalised  three years after closing. AstraZeneca received a payment of USD 250m on closing and will receive non-contingent payments of USD 100m and USD 50m in the first half of 2021.

“We have planned to take over the global rights for Atacand® since 2018 and are proud that it is now finally taking place,” said CHEPLAPHARM´s CEO Sebastian F. Braun.


Investor Relations topics

Back to top expand_less